CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 182 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Etanercept 0.8 mg/kg (up to 50 mg) once weekly subcutaneouslyAI-extracted
Key inclusion· 1
  • ✓Prior enrollment and participation in Amgen study 20030211 (NCT00078819)
Key exclusion· 1
  • ✕Serious or clinically significant adverse event on prior etanercept study (Amgen 20030211) related to etanercept

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00141921
NCT00141921Phase 3Completed
CompareCT.gov

An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Amgen·interventional·Posted Sep 2, 2005·Updated Oct 5, 2017

In Brief

A Phase 3 clinical trial evaluating Etanercept for Pediatric Plaque Psoriasis. Completed, enrolled 182 participants.

Detailed Summary

The purpose of this study is to evaluate the long-term safety and efficacy of etanercept in pediatric patients with moderate to severe psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Plaque Psoriasis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2, 2005
Enrollment StartAug 11, 2005
Primary CompletionDec 19, 2011
Study CompletionAug 16, 2017
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 20.8 years ago

Interventions

Etanerceptdrug

Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection